Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design

Journal of the National Cancer Institute

Volumn 86, Issue 20, 1994, Pages 1517-1524

  Chou, Ting Chao ^a   Motzer, Robert J ^a   Tong, Youzhi ^a   Bosl, George J ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; PACLITAXEL; TOPOTECAN; VINCRISTINE; VINCRISTINE SULFATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; COMPUTER ANALYSIS; DOSE RESPONSE; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; QUANTITATIVE ASSAY; TERATOCARCINOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ANTAGONISM; DRUG SYNERGISM; ETOPOSIDE; HUMAN; PACLITAXEL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TERATOCARCINOMA; TOPOTECAN; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0028153260     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/86.20.1517     Document Type: Article

References (42)

1. Bosl GJ, Gluckman R, Geller NL, et al: VAB- 6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol 4:1493-1499, 1986
2. Williams SD, Birch R, Einhom LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
3. Motzer RJ, Cooper K, Geller NL, et al: The role of tfosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66:2476-2481, 1990
4. Motzer RJ, Geller NL, Tan CC, et al: Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 67:1305-1310, 1991
5. Motzer RJ, Bosl GJ: High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions [see comment citation in Medline]. J Natl Cancer Inst 84:1703-1709 1992
6. Skehan P, Storeng R, Scudiero D, et al: New:olorimetnc cytotoxicity assay for anticancer- Irug screening. J Natl Cancer Inst 82:1107-1112, 1990
7. Zhou TC: Derivation and properties ol Michaelis-Menten type and Hill type equa- ions for reference ligands. J Theor Biol 59:253-276, 1976
8. Zhou TC: The median-effect principle and the:ombination index for quantitation of syner-;ism and antagonism, chap 2. In Synergism rnd Antagonism in Chemotherapy (Chou TC Hideout DC, eds) New York: Academic Press 1991, pp 61 -102
9. Zhou TC, Talalay P: A simple generalized aquation for the analysis of multiple inhibi- 10ns of Michaelis-Menten kinetic systems. J Biol Chem 252:6438-6442, 1977
10. Zhou TC, Talalay P: Generalized equations 'or the analysis of inhibitions of Michaelis- Menten and higher-order kinetic systems with wo or more mutually exclusive and nonex-:lusive inhibitors. Eur J Biochem 115:207-216, 1981
11. Zhou TC, Talalay P: Quantitative analysis ol iose-effect relationships: the combined effects rf multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55, 1984
12. Zhou, TC, Talalay P: Applications of the nedian-effect principle for the assessment of ow-dose risk of carcinogens and for the quan- itation of synergism and antagonism of:hemotherapeutic agents. In New Avenues in development Cancer Chemotherapy, Bristol- Myers Symposium series (Harrap KR, Con- lors TA, eds). New York: Academic Press. 1987, pp 37-64
13. Zhou J, Chou TC: Dose-effect analysis with nicrocomputers: quantitation of EDso, LDso, lynergism, antagonism, low-dose risk, recep- or-ligand binding and enzyme kinetics. In Manual and Software for IBM-PC. Zambridge, England: Biosoft, 1987
14. Zhou J: Quantitation of synergism and an- agonism of two or more drugs by com- luterized analysis, chap 6. In Synergism and Antagonism in Chemotherapy (Chou TC, Hideout DC, eds). New York: Academic Yess, 1991, pp 223-244
15. Zhou TC, Rideout D, Chou J, et al: Zhemotherapeutic synergism potentiation and intagomsm. In Encyclopedia of Human Biology, vol 2 (Dulbecco R, ed). New York: Academic Press, 1991, pp 371 -379
16. Vebb JL: Effect of More Than One Inhibitor. Enzyme and Metabolic Inhibitors, vol 1. New fork: Academic Press, 1963, pp 66-79, 112-488
17. Zhou TC, Tan QH, Sirotnak FM: Quantitation if the synergistic interaction of edatrexate and isplatin in vitro. Cancer Chemother Phar- nacol 31:259-264, 1993
18. lorwitz SB: Mechanism of action of taxol. [Tends Pharmacol Sci 13:134-136 1992 ichiff PB, Fant J, Horwitz SB: Promotion of nicrotubule assembly in vitro by taxol. Nature 177:665-667, 1979
19. Manfredi JJ, Horwitz SB: Taxol; an an- imitotic agent with a new mechanism of ac- ion. Pharmacol Ther25:83-125, 1984
20. Investigational Drug Branch, National Cancer institute: Taxol (NSC 12973) clinicalirochure, 1990
21. Towinsky EK, Cazenave LA, Donehower RC: 'axol: a novel investigational antimicrotubule gent. J Natl Cancer Inst 82:1247-1259, 1990
22. Rowinsky EK, Donehower RC: Taxol: twenty years later, the story unfolds [editorial]. J Natl Cancer Inst 83:1778-1781, 1991
23. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
24. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
25. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptolhecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
26. Burris HA, Rothenberg ML, Kuhn JG, et al: Clinical trials with the topoisomerase I inhibitors. Semin Oncol 19:663-669, 1992
27. Burris HA 3rd, Hartauske AR, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84:1816- 1820, 1992
28. Schneider E, Hsiang YH, Liu LF: DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21:149-183, 1990
29. Rozencweig M, Hoff DD, Von Abele R, et al: Cisplatin. In EORTC Cancer Chemotherapy Annual 2 (Pinedo HM, ed). Amsterdam: Ex- cerpta Medica, 1980, pp 107-117
30. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
31. Bosl GJ, Geller NL, Bajorin D, et al: A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231-1238, 1988
32. Durand RE, Goldie JH: Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 71:673-679, 1987
33. Zwelling LA, Michaels S, Schwartz H, et al: DNA cross-linking as an indicator of sensitivity and resistance of mouse LI210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res 41:640-649, 1981
34. Eastman A: Reevaluation of interaction of cis-dichloro-(ethylenediamine)platinum(II) with DNA. Biochemistry 25:3912-3915, 1986
35. Vogelzang NJ, Raghavan D, Kennedy BJ: VP- 16213 (etoposide): the mandrake root from Issyk-Kul. Am J Med 72:136144, 1982
36. Chen GL, Yang L, Rowe TC, et al: Noninter- calative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259:13560-13566, 1985
37. Estey EH, Silberman BM, Beran M, et al: The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)- methanesulfon-m-anisidide (m-AMSA) or 4-(4, 6-0-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Biochem Biophys Res Commun 144:787-793, 1987
38. O’Dwyer PJ, Leyland-Jones B, Alonso MT, et al: Etoposide (VP-16213). Current status of an active anticancer drug. N Engl J Med 312:692-700, 1985
39. Bender RA, Chabner BA: Tubulin binding agents. In Pharmacological Principles of Cancer Treatment (Chabner BA, ed). Phildelphia: Saunders, 1982, pp 256-268
40. Calabresi P, Schein PS, Rosenberg SA, eds: Medical Oncology. New York: Macmillan, 1985
41. Citardi MJ, Rowinsky EK, Schaefer KL, et al: Sequence-dependent cytotoxicity between cisplatin (C) and the antimicrotubule agents taxol (T) and vincristine (V). Proc Amer Assoc Cancer Res 31:410, 1990
42. Motzer RJ, Bosl GJ: High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions [see comment citation in Medline]. J Natl Cancer Inst 84:1703-1709, 1992